What's Hot & What's Not in Antibody-Drug Conjugates (ADC) Licensing
Antibody-Drug Conjugates combine the specificity of the antibody recognizing the antigen target with the potent tumor-killing effects of a cytotoxic, attached typically via a linker. 6 ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by 2024 (GlobalData). Currently, about 100 ADCs are in clinical development.
In this discussion, our expert panel will answer the following questions,
- What targets are suitable?
- What are the trends in linkers and the drugs to be attached to the antibodies? What are the indications being pursued?
- How are companies dealing with the complexities of internalization and high cost of goods? What kind of data will drive an ADC licensing deal?
- How do the ADCs fit in the world of immuno-oncology?
- What is the future for ADCs?
We invite you to join us from your desk on Jan. 24th from 11am to 12:30pm PT to attend 'What's Hot & What's Not in Antibody-Drug Conjugates (ADC) Licensing.’ The virtual discussion will be moderated by biopharma partnering expert, Linda Pullan, PhD, of Pullan Consulting along with Jeff Bockman, PhD, the Head of Oncology for Cello Health BioConsulting, formerly Defined Health. The panel will feature ADC experts who will provide unique insight and a look into the challenges and future of ADCs.
Participants are encouraged to join the discussion and will have the opportunity to ask questions during and after the discussion. Register now.
Full speaker bios below...
Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.